Physician profile
Julia M Shi
NPI 1972513125
$8,891.55
in general payments reported to CMS, 2019-2025
23 companies · $281 in 2025
The $281 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,080 · 2020: $1,589 · 2021: $309 · 2022: $220 · 2023: $81.49 · 2024: $331 · 2025: $281.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $694.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $693.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $6,093.39 | 2019-2024 | Epclusa |
| Allergan, INC. | $393.87 | 2019-2020 | |
| Abbvie INC. | $353.91 | 2019-2025 | Ubrelvy |
| Indivior INC. | $330.29 | 2019-2025 | Sublocade |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $266.92 | 2019-2021 | |
| Intersect Ent, INC. | $264.27 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $203.75 | 2019-2020 | |
| Pfizer INC. | $169.49 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $152.96 | 2019-2025 | Airsupra |
| Genzyme Corporation | $125.01 | 2022 | |
| Medtronic, INC. | $123.67 | 2025 | Stealthstation S8 Platform |
| Orexo US, INC. | $95.87 | 2019-2020 | |
| Alkermes, INC. | $87.49 | 2019-2023 | Vivitrol |
| Otsuka America Pharmaceutical, INC. | $47.39 | 2024-2025 | Rexulti |
| Neos Therapeutics, LP | $35.10 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mdd US Operations, LLC | $30.21 | 2020 | |
| Kaleo, INC. | $25.65 | 2019 | |
| Glaxosmithkline, LLC. | $19.58 | 2025 | Nucala |
| Viiv Healthcare Company | $19.57 | 2020 | |
| Biodelivery Sciences International, INC. | $15.03 | 2019 | |
| Vertical Pharmaceuticals, LLC | $13.93 | 2024 | Relexxii |
| Optinose US, INC. | $13.59 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $10.61 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julia Shi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.